Monoclonal antibodies that target CD20 expressing B cells represent an important new
treatment option for patients with multiple sclerosis (MS). B‐cell‐depleting therapy is highly …

Multiple Sclerosis (MS) is an inflammatory demyelinating disease of the central nervous
system (CNS) which involves a complex interaction between immune system and neural …

While no single model can exactly recapitulate all aspects of multiple sclerosis (MS), animal
models are essential in understanding the induction and pathogenesis of the disease and to …

Multiple sclerosis (MS) is a multifocal demyelinating disease of the central nervous system
(CNS) leading to the progressive destruction of the myelin sheath surrounding axons. It can …

Whether B cells serve as antigen-presenting cells (APCs) for activation of pathogenic T cells
in the multiple sclerosis model experimental autoimmune encephalomyelitis (EAE) is …

Myelin oligodendrocyte glycoprotein (MOG), a member of the immunoglobulin (Ig)
superfamily, is a myelin protein solely expressed at the outermost surface of myelin sheaths …

To assess the importance of B cell control of T cell differentiation, we analyzed the course of
the T helper type 1 (TH1)-driven disease experimental autoimmune encephalomyelitis in …

Objective Rituximab, a monoclonal antibody selectively depleting CD20+ B cells, has
demonstrated efficacy in reducing disease activity in relapsing‐remitting multiple sclerosis …

EAE is a mouse T cell–mediated autoimmune disease of the CNS used to model the human
condition MS. The contributions of B cells to EAE initiation and progression are unclear. In …

Cytotoxic T lymphocyte antigen-4 (CTLA-4) is essential for immunological (self-) tolerance,
but due to the early fatality of CTLA-4 KO mice, its specific function in central and peripheral …